恶性血液病患者侵袭性真菌病的研究进展

doi:10.3969/j.issn.1671-2587.2025.02.019

临床输血与检验 ›› 2025, Vol. 27 ›› Issue (2): 274-282.DOI: 10.3969/j.issn.1671-2587.2025.02.019

恶性血液病患者侵袭性真菌病的研究进展

沈汉影, 汤宝林, 强萍

中国科学技术大学附属第一医院（安徽省立医院）,安徽合肥 230001

收稿日期:2024-12-02 出版日期:2025-04-20 发布日期:2025-04-17
通讯作者: 强萍,主要从事血液病诊治和造血干细胞移植,（E-mail） qiangping8663@163.com。共同通信作者：汤宝林,主要从事血液病诊治和造血干细胞移植,（E-mail）zwcrystalbl@163.com。
作者简介:沈汉影,主要从事恶性血液病的诊断和治疗,（E-mail）Hanyingshen @126.com。

Received:2024-12-02 Online:2025-04-20 Published:2025-04-17

摘要/Abstract

摘要： 近年来恶性血液病患者的治疗方案不断优化,造血干细胞移植、靶向及免疫治疗改善了患者的预后,尽管大部分患者采用了预防策略,但恶性血液病患者侵袭性真菌病（invasive fungal disease, IFD）的发病率仍呈上升趋势。IFD的临床症状常缺乏特异性,其诊断具有挑战性,通常依赖于微生物学、影像学以及组织病理学检查;高通量测序技术等新型技术的飞速发展,有望提高IFD的诊断效能。早期识别高危患者,并给予预防性抗真菌治疗,可以降低IFD的发生率和死亡率。此外,准确把握启动治疗的时机及选择合理的抗真菌药物至关重要;IFD的治疗策略中,经验性抗真菌治疗、诊断驱动治疗和目标治疗占据核心地位。本文对恶性血液病患者IFD的流行病学、病原学、预防策略及治疗方案进行了系统综述,为恶性血液病患者的临床治疗提供科学依据和决策支持。

中图分类号:

R519R551.1

沈汉影, 汤宝林, 强萍. 恶性血液病患者侵袭性真菌病的研究进展[J]. 临床输血与检验, 2025, 27(2): 274-282.

参考文献

[1] SIEGEL RL,GIAQUINTO AN,JEMAL A,et al.Cancer statistics,2024[J].CA A Cancer J Clin,2024,74(1):12-49.
[2] WANG L,WANG Y,HU J,et al.Clinical risk score for invasive fungal diseases in patients with hematological malignancies undergoing chemotherapy:China Assessment of Antifungal Therapy in Hematological Diseases(CAESAR)study[J].Front Med,2019,13(3):365-377.
[3] SUN Y Q,MENG F Y,HAN M Z,et al.Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China:a multicenter prospective observational study[J].Biol Blood Marrow Transplant, 2015,21(6):1117-1126.
[4] SUN Y Q,HUANG H,CHEN J,et al.Invasive fungal infection in patients receiving chemotherapy for hematological malignancy:a multicenter,prospective,observational study in China[J].Tumour Biol,2015,36(2):757-767.
[5] GANGNEUX J P,PADOIN C,MICHALLET M, et al.Outcomes of antifungal prophylaxis in high-risk haematological patients(AML under intensive chemotherapy):the SAPHIR prospective multicentre study[J].J Fungi(Basel),2020,6(4):281.
[6] SPRUTE R,NACOV J A,NEOFYTOS D,et al.Antifungal prophylaxis and pre-emptive therapy:when and how?[J].Mol Aspects Med,2023,92:101190.
[7] WANG J,ZHOU M,XU J Y,et al.Comparison of antifungal prophylaxis drugs in patients with hematological disease or undergoing hematopoietic stem cell transplantation:a systematic review and network meta-analysis[J].JAMA Netw Open,2020,3(10):e2017652.
[8] BERGAMASCO M D,PEREIRA C A P,ARRAIS-RODRIGUES C,et al.Epidemiology of invasive fungal diseases in patients with hematologic malignancies and hematopoietic cell transplantation recipients managed with an antifungal diagnostic driven approach[J].J Fungi(Basel),2021,7(8):588.
[9] GOLD J A W,TOLU S S,CHILLER T,et al.Incidence of invasive fungal infections in patients initiating ibrutinib and other small molecule kinase inhibitors-United States,July 2016-June 2019[J].Clin Infect Dis, 2022,75(2):334-337.
[10] LITTLE J S,KAMPOURI E,FRIEDMAN D Z,et al.The burden of invasive fungal disease following chimeric antigen receptor T-cell therapy and strategies for prevention[J].Open Forum Infect Dis,2024,11(6):ofae133.
[11] MCCORT M E,TSAI H.Epidemiology of invasive candidiasis in patients with hematologic malignancy on antifungal prophylaxis[J].Mycopathologia,2023,188(6): 885-892.
[12] KIMURA S I,KAMEDA K,HARADA K,et al.Risk and predictive factors for candidemia after allogeneic hematopoietic cell transplantation:JSTCT transplant complications working group[J].Transplant Cell Ther, 2022,28(4):209.e1-209209.e9.
[13] CHEN C Y,SHENG W H,TIEN F M,et al.Clinical characteristics and treatment outcomes of pulmonary invasive fungal infection among adult patients with hematological malignancy in a medical centre in Taiwan, 2008-2013[J].J Microbiol Immunol Infect,2020,53(1): 106-114.
[14] FANG W J,WU J Q,CHENG M R,et al.Diagnosis of invasive fungal infections:challenges and recent developments[J].J Biomed Sci,2023,30(1):42.
[15] DONNELLY JP,CHEN S C,KAUFFMAN C A,et al.Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium[J].Clin Infect Dis,2020,71(6):1367-1376.
[16] YAN G,CHEW K L,CHAI L Y A.Update on non-culture-based diagnostics for invasive fungal disease[J].Mycopathologia,2021,186(5):575-582.
[17] AGNELLI C,BOUZA E,DEL CARMEN MARTÍNEZ-JIMÉNEZ M,et al.Clinical relevance and prognostic value of persistently negative(1,3)-β-D-glucan in adults with candidemia:a 5-year experience in a tertiary hospital[J].Clin Infect Dis,2020,70(9):1925-1932.
[18] LASS-FLÖRL C,SAMARDZIC E,KNOLL M.Serology anno 2021-fungal infections:from invasive to chronic[J].Clin Microbiol Infect,2021,27(9):1230-1241.
[19] MAH J,NICHOLAS V,TAYYAR R,et al.Superior accuracy of Aspergillus plasma cell-free DNA polymerase chain reaction over serum galactomannan for the diagnosis of invasive aspergillosis[J].Clin Infect Dis,2023,77(9):1282-1290.
[20] PARK S Y,ARDURA M I,ZHANG S X.Diagnostic limitations and challenges in current clinical guidelines and potential application of metagenomic sequencing to manage pulmonary invasive fungal infections in patients with haematological malignancies[J].Clin Microbiol Infect,2024,30(9):1139-1146.
[21] ZHANG X Y,ZHANG L F,LI Y,et al.Clinical performance of metagenomic next-generation sequencing for diagnosis of invasive fungal disease after hematopoietic cell transplant[J].Front Cell Infect Microbiol,2024,14: 1210857.
[22] HELDMAN M R,AHMED A A,LIU W,et al.Serial quantitation of plasma microbial cell-free DNA before and after diagnosis of pulmonary invasive mold infections after hematopoietic cell transplant[J].J Infect Dis,2024, 229(2):576-587.
[23] HEMATOLOGISTS C A,CHINESE Invasive Fungal Infection Working Group.The Chinese guidelines for the diagnosis and treatment of invasive fungal disease in patients with hematological disorders and cancers (the 6th revision)[J].Zhonghua Nei Ke Za Zhi,2020,59(10):754-763.
[24] WASYLYSHYN A I,LINDER K A,KAUFFMAN C A,et al.Invasive fungal disease in patients with newly diagnosed acute myeloid leukemia[J].J Fungi(Basel),2021, 7(9):761.
[25] GHEZ D,CALLEJA A,PROTIN C,et al.Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib[J].Blood,2018,131(17):1955-1959.
[26] STEMLER J,DE JONGE N,SKOETZ N,et al.Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies:a systematic review and expert consensus recommendation from the European Hematology Association[J].Lancet Haematol,2022,9(5):e361-e373.
[27] TEH B W,YEOH D K,HAEUSLER G M,et al.Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation,2021[J].Intern Med J,2021,51(Suppl 7): 67-88.
[28] STEMLER J,MELLINGHOFF S C,KHODAMORADI Y,et al.Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies:2022 update of the recommendations of the Infectious Diseases Working Party(AGIHO)of the German Society for Haematology and Medical Oncology(DGHO)[J].J Antimicrob Chemother,2023,78(8):1813-1826.
[29] MEDICAL MYCOLOGY SOCIETY OF CHINESE MEDICINE AND EDUCATION ASSOCIATION, CHINESE SOCIETY OF HEMATOLOGY,CHINESE MEDICAL ASSOCIATION.Chinese expert consensus for invasive fungal disease in patients after hematopoietic stem cell transplantation(2023)[J].Zhonghua Xue Ye Xue Za Zhi, 2023,44(2):92-97.
[30] PIZZO P A,ROBICHAUD K J,GILL F A,et al.Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia[J].Am J Med,1982,72(1):101-111.
[31] KO B S,CHEN W T,KUNG H C,et al.2016 guideline strategies for the use of antifungal agents in patients with hematological malignancies or hematopoietic stem cell transplantation recipients in Taiwan[J].J Microbiol Immunol Infect,2018,51(3):287-301.
[32] ALEXANDER B D,LAMOTH F,HEUSSEL C P,et al.Guidance on imaging for invasive pulmonary aspergillosis and mucormycosis:from the imaging working group for the revision and update of the consensus definitions of fungal disease from the EORTC/MSGERC[J].Clin Infect Dis,2021,72(Suppl 2):S79-S88.
[33] GUTIÉRREZ-VILLANUEVA A,CALDERÓN-PARRA J,CALLEJAS-DIAZ A,et al.What do we know about the usefulness of 18F-FDG PET-CT for the management of invasive fungal infection? an international survey[J].Mycopathologia,2024,189(5):84.
[34] LONGHITANO A,ALIPOUR R,KHOT A,et al.The role of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography(FDG PET/CT)in assessment of complex invasive fungal disease and opportunistic co-infections in patients with acute leukemia prior to allogeneic hematopoietic cell transplant[J].Transpl Infect Dis,2021,23(3):e13547.
[35] PAPPAS P G,KAUFFMAN C A,ANDES D R,et al.Clinical practice guideline for the management of candidiasis:2016 update by the infectious diseases society of America[J].Clin Infect Dis,2016,62(4):e1-50.
[36] KEIGHLEY C,COOLEY L,MORRIS A J,et al.Consensus guidelines for the diagnosis and management of invasive candidiasis in haematology,oncology and intensive care settings,2021[J].Intern Med J,2021,51(Suppl 7):89-117.
[37] NEOFYTOS D,STEINBACH W J,HANSON K, et al.American society for transplantation and cellular therapy series,#6:management of invasive candidiasis in hematopoietic cell transplantation recipients[J].Transplant Cell Ther,2023,29(4):222-227.
[38] CHINESE Adult Candidiasis Diagnosis and Management Expert Consensus Group.Chinese consensus on the diagnosis and management of adult candidiasis[J].Zhonghua Nei Ke Za Zhi,2020,59(1):5-17.
[39] DOUGLAS A P,SMIBERT O C,BAJEL A,et al.Consensus guidelines for the diagnosis and management of invasive aspergillosis,2021[J].Intern Med J,2021,51(Suppl 7):143-176.
[40] ASTHMA Group of Chinese Thoracic Society.Expert consensus on the diagnosis and treatment of allergic bronchopulmonary aspergillosis(2022 update)[J].Zhonghua Jie He He Hu Xi Za Zhi,2022,45(12):1169-1179.
[41] MARTÍN GÓMEZ M T,SALAVERT LLETÍ M.Mucormycosis:Current and future management perspective[J].Rev Iberoam Micol,2021,38(2):91-100.
[42] CORNELY O A,ALASTRUEY-IZQUIERDO A,ARENZ D,et al.Global guideline for the diagnosis and management of mucormycosis:an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium[J].Lancet Infect Dis,2019,19(12):e405-e421.
[43] MEDICAL MYCOLOGY SOCIETY OF CHINESE MEDICINE AND EDUCATION ASSOCIATION, CHINESE MUCORMYCOSIS EXPERT CONSENSUS GROUP.Expert consensus on diagnosis and management of mucormycosis in China[J].Zhonghua Nei Ke Za Zhi, 2023,62(6):597-605.
[44] HOENIGL M,SALMANTON-GARCÍA J,WALSH T J, et al.Global guideline for the diagnosis and management of rare mould infections:an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology[J].Lancet Infect Dis,2021,21(8):e246-e257.
[45] NEOH C F,CHEN S C,LANTERNIER F,et al.Scedosporiosis and lomentosporiosis:modern perspectives on these difficult-to-treat rare mold infections[J].Clin Microbiol Rev,2024,37(2):e0000423.
[46] NUCCI M,ANAISSIE E.Invasive fusariosis[J].Clin Microbiol Rev,2023,36(4):e0015922.
[47] CHEN S C,PERFECT J,COLOMBO A L,et al.Global guideline for the diagnosis and management of rare yeast infections:an initiative of the ECMM in cooperation with ISHAM and ASM[J].Lancet Infect Dis,2021,21(12): e375-e386.

恶性血液病患者侵袭性真菌病的研究进展

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们